Someone else's clock has started running against them: the company is being paid to solve a problem that is already cost
The model's full reasoning — Q4 2017 call → NOWe need to answer the question based only on the transcript. The question is whether management describes a situation where counterparties are already losing something real and ongoing (a "running meter") because they don't have the company's product, and that these counterparties are already acting like the meter is running (e.g., pressing, paying more, etc.). And this dynamic is generating meaningful business still ahead. We need to parse the transcript. The company is Pacira Pharmaceuticals. They make EXPAREL, a non-opioid analgesic for post-surgical pain. The context: opioid epidemic, they position EXPAREL to address it. They have partnerships, J&J, CMS, payers, health systems. Look for any description of a cost/loss to counterparties for not having EXPAREL. Perhaps: hospitals losing money because of opioid-related costs? Or payers paying more? Or patients suffering? But the question is specifically about counterparties like customers, partners, etc. Management may describe that payers are already recognizing economic advantage, but is there a running meter? For example, "commercial payers already recognize the economic advantage of reimbursing EXPAREL separately... They are supporting enhanced recovery after surgery protocols with EXPAREL and shifting many inpatient procedures to the outpatient setting, which is yielding a savings of roughly 40% per case." That's a benefit, but not a loss for going without. The question asks: Does management describe that counterparties are ALREADY LOSING something REAL AND ONGOING for as long as they do not have what the company provides? That is, a cost of delay. Could be: patients becoming opioid addicted, but that's not a counterparty to the company? The counterparty could be the payer, hospital, surgeon. Is there any mention of a running meter? Perhaps CMS? "We are currently working with CMS policymakers to achieve an off-cycle change around reimbursement practices that bundle EXPAREL within their fixed payment..." Not losing. Look at the section about reimbursement: "Commercial payers already recognize the economic advantage of reimbursing EXPAREL separately under C9290. They are supporting enhanced recovery after surgery protocols with EXPAREL and shifting many inpatient procedures to the outpatient setting, which is yielding a savings of roughly 40% per case." This describes that payers are already benefiting.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
SYM · Q3 2022 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...YES The transcript shows management describing customers' ongoing pain from labor shortages and broken supply chains that prevent them from handling demand, with customers actively clamoring for faster deployments and wanting the system as quickly as possible.
CRL · Q2 2022 → YESThe question is whether management describes that their counterparties are already losing something real and ongoing — money, output, access, standing, time, or an opportunity — for as long as they do...
GTES · Q4 2021 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...